Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association between response to triptans and response to erenumab: real-life data
Ilaria Frattale, Valeria Caponnetto, Alfonsina Casalena, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
Linda Al‐Hassany, Peter J. Goadsby, A.H. Jan Danser, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 284-294
Closed Access | Times Cited: 96
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 41
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 64
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology (2022) Vol. 30, Iss. 1, pp. 224-234
Open Access | Times Cited: 38
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
Bianca Raffaelli, Mira Pauline Fitzek, Lucas Hendrik Overeem, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 38
Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
Keiko Ihara, Seiya Ohtani, Narumi Watanabe, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 35
Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study
Hyoung Cheol Lee, Soohyun Cho, Byung‐Kun Kim
Neurological Sciences (2023) Vol. 44, Iss. 7, pp. 2455-2463
Closed Access | Times Cited: 26
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Journal of Neurology (2021) Vol. 29, Iss. 4, pp. 1198-1208
Closed Access | Times Cited: 55
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 37
Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
Magdalena Nowaczewska, Marcin Straburzyński, Marta Waliszewska‐Prosół, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 28
The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
William Kristian Karlsson, Håkan Ashina, Christopher Kjær Cullum, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 18
Predictors of Response to Treatment With Anti-calcitonin Gene-Related Peptide (CGRP) Antibodies in Real-World Patients With Episodic Migraine: A Two- and Four-Month Prospective Study
Abouch Valenty Krymchantowski, Carla Jevoux, Raimundo Pereira Silva‐Néto, et al.
Cureus (2025)
Open Access
Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
Alicia Alpuente, Anna de la Torre-Suñe, Edoardo Caronna, et al.
Cephalalgia (2023) Vol. 43, Iss. 8
Open Access | Times Cited: 12
Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials
Christian Lampl, Viktoria Kraus, Katrina Lehner, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Low adherence to the guideline for the acute treatment of migraine
Astrid Olesen, Henrik Winther Schytz, Sisse Rye Ostrowski, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 16
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine
Emmanouil V. Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 386-386
Open Access | Times Cited: 3
What do patients’ efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry
Ruth Ruscheweyh, Thomas Dresler, Stefanie Förderreuther, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311748-033310242311748
Open Access | Times Cited: 8
Advances in CGRP Monoclonal Antibodies as Migraine Therapy
Suruchi Aditya, Aditya Rattan
Saudi Journal of Medicine and Medical Sciences (2023) Vol. 11, Iss. 1, pp. 11-18
Open Access | Times Cited: 7
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Rimegepant as an acute treatment in a refractory migraine patient non-responder to two anti-CGRP monoclonal antibodies and triptans: Case report and pharmacological considerations
Andrea Burgalassi, Giulia Vigani, Alberto Boccalini, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 2
Pituitary cyclase‐activating polypeptide targeted treatments for the treatment of primary headache disorders
Nazia Karsan, Lars Edvinsson, László Vécsei, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 7, pp. 1654-1668
Open Access | Times Cited: 2
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population
Yu-Chin An, Kuo‐Sheng Hung, Chih‐Sung Liang, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Predictors of galcanezumab response in a real-world study of Korean patients with migraine
Seung Ae Kim, Hyemin Jang, Mi Ji Lee
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada
Marzieh Eghtesadi, Élizabeth Leroux, M. Gabrielle Pagé
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 733-739
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top